Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-03-28
2006-03-28
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
Reexamination Certificate
active
07019112
ABSTRACT:
Melanoma-specific, A1- and A3-restricted CTL epitopes have been identified in tyrosinase and pMel-17, respectively, and may be used in the design of vaccines.
REFERENCES:
patent: 4478823 (1984-10-01), Sanderson
patent: 9414459 (1994-07-01), None
patent: 9522561 (1995-08-01), None
patent: 9525122 (1995-09-01), None
patent: 9529193 (1995-11-01), None
patent: 9740156 (1997-10-01), None
patent: 9833810 (1998-08-01), None
Burgess et al. J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252 (1988).
Tao et al., The Journal of Immunology, 143:2595-2601 (1989).
Bowie et al (Science, 247:1306-1310, 1990.
Yamshchikov, G, et al, 2001, Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations, Clinical Cancer Research, vol. 7, No. 3 supplement, pp. 909s-916s.
Bodey, B, et al, 2000, Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, vol. 20, pp. 2665-2676.
Cox, AL, et al, 1994, Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, vol. 264, pp. 716-719.
Ezzell, C, 1995, Cancer “vaccines”: an idea whose time has come?, Journal of NIH Research, vol. 7, pp. 46-49.
Splitler, LE, 1995, Cancer vaccines: the interferon analogy, Cancer Biotherapy, vol. 10, No. 1, pp. 1-3.
Boon, T, 1992, Toward a genetic analysis of tumor rejection antigens, Advances in Cancer Research, vol. 58, pp. 177-210.
Arceci, RJ, 1998, The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, vol. 76, pp. 80-93.
Lee, K-H, et al, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, vol. 163, pp. 6292-6300.
Zaks, TZ, et al, 1998, Immunization with a peptide epitope (p369-377) from HER-2
eu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2
eu+ tumors, Cancer Research, vol. 58, pp. 4902-4908.
Gao, P, et al, 2000, Tumor vaccination that enhances antitumor T-cell responses does not inhibit th growth of established tumors, Journal of Immunotherapy, vol. 23, No. 6, pp. 643-653.
Hu, X, et al, 1996, Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide, Cancer Research, vol. 56, pp. 2479-2483.
Jaeger, E, et al, 1996, Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, International Journal of Cancer, vol. 66, No. 2, pp. 162-169.
Mukherji, B, et al, 1995, Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization, Proceedings of the National Academy of Science USA, vol. 92, pp. 8078-8082.
Timmerman, JM, et al, 1999, Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, vol. 50, pp. 507-529.
Tockman, MS, et al, 1992, Considerations in bringing a cancer biomarker to clinical application, Cancer Research, vol. 52, Suppl., pp. 2711s-2718s.
Gura, T, 1997, Systems for identifying drugs are often faulty, Science, vol. 278, pp. 1041-1042.
Adema et al., Melanocyte Lineage-Specific Antigens Recognized by Monoclonal Antibodies NKI-beteb, HMB-50, and HMB-45 are Encoded by a Single cDNA.,Am. J. Path, vol. 143, No. 6, pp. 1579-1585, Dec. 1993.
Jaeger et al., Generation of Cytotoxic T-Cell Responses with Synthetic Melanoma-Associated Peptides In VIVO: Implications for Tumor Vaccines with Melanoma-Associated Antigens,Int. J. Cancer, vol. 66, pp. 162-169, 1996.
Slingluff et al., Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes is Mediated by at Least Six Shared Peptide Epitopes,J. Immunol., vol. 150, No. 7, pp. 2955-2963, 1993.
Vose et al., Human Tumour Antigens Defined by Cytotoxicity and Proliferative Responses of Cultured Lymphoid Cells,Nature, vol. 296, pp. 359-361, Mar. 25, 1982.
Knuth et al., T-Cell-Mediated Cytotoxicity Against Autologous Malignant Melanoma: Analysis with Interleukin 2-Dependent T-Cell Cultures,Proc. Natl. Acad. Sci. USA, vol. 81, pp. 3511-3515, Jun. 1984.
Slingluff et al., Human T Cells Specifically Activated Against Autologous Malignant Melanoma,Arch Surg, vol. 122, pp. 1407-1411, Dec. 1987.
Slingluff et al., Melanoma-Specific Cytotoxic T Cells Generated from Peripheral Blood Lymphocytes,Ann. Surg., vol. 210, No. 2, pp. 194-202, Aug. 1989.
Muul et al., Identification of Specific Cytolytic Immune Responses Against Autologous Tumor in Humans Bearing Malignant Melanoma,The Journal of Immunology, vol. 138, No. 3, pp. 989-995, Feb. 1987.
Van Den Eynde et al., Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL,Int. J. Cancer, vol. 44, pp. 634-640, 1989.
Anichini et al., Clonal Analysis of Cytotoxic T-Lymphocyte Response to Autologous Human Metastatic Melanoma,Int. J. Cancer, vol. 35, pp. 683-689, 1985.
Elliott et al., Naturally Processed Peptides,Nature, vol. 348, pp. 195-197, Nov. 15, 1990.
Townsend et al., Antigen Recognition By Class I-Restricted T Lymphocytes,Ann. Rev. Immunol., vol. 7, pp. 601-624, 1989.
Hunt et al., Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry,Science, vol. 255, pp. 1261-1263, Mar. 6, 1992.
Van Der Bruggen et al., A Gene Encoding an Antigen Recognized by Cytolic T Lymphocytes on a Human Melanoma,Science, vol. 254, pp. 1643-1647, Dec. 13, 1991.
Traversari et al., A Nonapeptide Encoded by Human Gene MAGE-1 is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E,J. Exp. Med., vol. 176, pp. 1453-1457, Nov. 1992.
Brichard et al., The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas,J. Exp. Med., vol. 178, pp. 489-495, Aug. 1993.
Wolfel et al., Two Tyrosinase Nonapeptides Recognzied on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes,Eur. J. Immunol., vol. 24, pp. 759-763, 1994.
Boon et al., Tumor Antigens Recognized by T Lymphocytes,Ann. Rev. Immunol., vol. 12, pp. 337-365, 1994.
Finn, Olivera J., Tumor-Rejection Antigens Recognized by T Lymphocytes,Current Opinion in Immunology, vol. 5, pp. 701-708, 1993.
Cox et al., Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell . . . ,Science, vol. 264, pp. 716-719, Apr. 1994.
Engelhard et al., Mass Spectrometric Analysis of Peptides Associated with the Human Class I MHC Molecules HLA-A2.1 and HLA-B7 and Identification of Structural Features that Determine Binding,Chem Immunol. Basel, Karger, vol. 57, pp. 39-62, 1993.
Kwon et al., A Melanocyte-Specific Gene, Pmel 17, Maps Near the Silver Coat Color Locus on Mouse Chromosome 10 and is in a Syntenic Region on Human Chromosome 12,Proc. Natl. Acad. Sci., USA, vol. 88, pp. 9228-9232, Oct. 1991.
Anichini et al., Melanoma Cells and Normal Melanocytes Share Antigens Recognized by HLA-A2-restricted Cytotoxic T Cell Clones from Melanoma Patients,J. Exp. Med, vol. 177, pp. 989-998, Apr. 1993.
Van Bleek et al., Isolation of an Endogenuously Processed Immunodominant Viral Peptide from the Class I H-2KbMolecule,Nature, vol. 348, pp. 213-216, Nov. 1990.
Kawakami et al., Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 6458-6462, Jul. 1994.
Kawakami et al., Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3515-3519, Apr. 1994.
Mandelbolm et al., CTL Induction by a Tumour-Associated Antigen Octapeptide Derived from a Murine Lung Carcinoma,Nature, vol. 369, pp. 67-71, May 1994.
Henderson et al., Direct Identification of an Endogenous Peptide Recognized by Multiple HLA-A2.1-Specific Cytotoxic T Cells,Proc. Natl. Acad. Sci. USA, vol. 90, pp. 10275-10279, Nov. 1993.
Huczko et al., Characteristics of Endogenous Peptides Eluted fromt he Class I MHC Molecule HLA
Cox Andrea L.
Engelhard Victor H.
Hendrikson Ronald C.
Hunt Donald F.
Kittlesen David
Fulbright & Jaworski LLP
Helms Larry R.
Rawlings Stephen L.
University of Virginia Patent Foundation
LandOfFree
Peptides recognized by melanoma-specific A1-, A2- and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides recognized by melanoma-specific A1-, A2- and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides recognized by melanoma-specific A1-, A2- and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3577639